Latest coverage
- Press releases
- Country: United States
Landmark NIH-funded study across nearly 2,400 participants validates circular RNA as a dynamic new molecular intelligence layer, capturing active changes across multiple neurodegenerative pathways years before cognitive decline: Superior Progression Prediction: Demonstrates a 2.92 Hazard...
- Press releases
- Country: United States
Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer's disease (AD) who were α-synuclein positive, a subgroup associated with higher amyloid burden and faster clinical decline TOKYO and CAMBRIDGE, Mass., Nov. 19,...
- Press releases
- Country: United States
STOCKHOLM, November 18, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) study[1]. The data showed that patients treated with Leqembi had a 76% lower rate of...
- Press releases
- Country: United States
Longer-term results from the Phase 2 CELIA study suggest clinical benefit may build over time NEW YORK, Nov. 18, 2026 /PRNewswire/ -- Today at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Biogen presented new data from the Phase 2 CELIA study of diranersen...
- Press releases
- Country: United States
Largest analysis of LEQEMBI LEADER study reported to date includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe AD, expanded subcutaneous maintenance experience, and additional sex-based outcomes TOKYO and CAMBRIDGE, Mass., Nov. 18,...
- Press releases
- Country: United States
Benefits of continuous lecanemab treatment in early Alzheimer's disease accrue over time Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI 62% of patients with low tau showed improvement in cognitive function and activities of daily living...
- Press releases
- Country: United States
Studies presented at the premier global forum for Alzheimer's disease clinical research span digital cognitive assessment validation, amyloid PET prediction, claims-based dementia risk stratification, and patient-defined outcomes BOSTON, Nov. 16, 2026 /PRNewswire/ -- Linus Health, an...
- Press releases
- Country: United States
Analysis of fully remote program included 28 patients across 10 states, treated with lecanemab or donanemab. BOSTON, Nov. 16, 2026 /PRNewswire/ -- Synapticure, a national, virtual specialty practice for neurodegenerative disease, today announced data showing that amyloid-targeted therapy...